CTRI/2017/03/007979已完成4 期
International, randomized, open label study to compare the safety and efficacy of lixisenatide vs sulfonylurea on top of basal insulin treatment in Type 2 Diabetes Mellitus subjects who elect to fast during Ramadan - LixiRam
SanofiSynthelabo India Private Limited0 个研究点目标入组 150 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Patients with T2DM,
- •For complete list of inclusion criteria, please contact sponsor
排除标准
- •HbA1c at screening visit < 7.5% or > 10%
- •For complete list of exclusion criteria, please contact sponsor
研究者
相似试验
进行中（未招募）
不适用
A randomised, open-label, multi-national study to investigate the impact of bone marker feedback (at 2 months) on adherence to once monthly Ibandronate treatment for post-menopausal osteoporosis (PMO) - BEATRISosteoporosis in postmenopausal womenMedDRA version: 8.0Level: PTClassification code 10031285EUCTR2005-005399-34-BE.V. Roche S.A.800
进行中（未招募）
1 期
A randomised, open-label, multi-national study to investigate the impact of bone marker feedback (at 2 months) on adherence to once monthly Ibandronate treatment for post-menopausal osteoporosis (PMO) - BEATRISosteoporosis in postmenopausal womenEUCTR2005-005399-34-IE.V. Roche S.A.800
进行中（未招募）
不适用
A randomised, open-label, multi-national study to investigate the impact of bone marker feedback (at 2 months) on adherence to once monthly Ibandronate treatment for post-menopausal osteoporosis (PMO) - BEATRISosteoporosis in postmenopausal womenEUCTR2005-005399-34-AT.V. Roche S.A.800
进行中（未招募）
不适用
A randomised, open-label, multi-national study to investigate the impact of bone marker feedback (at 2 months) on adherence to once monthly Ibandronate treatment for post-menopausal osteoporosis (PMO) - BEATRISosteoporosis in postmenopausal womenEUCTR2005-005399-34-GR.V. Roche S.A.580
进行中（未招募）
不适用
A randomised, open-label, multi-national study to investigate the impact of bone marker feedback (at 2 months) on adherence to once monthly Ibandronate treatment for post-menopausal osteoporosis (PMO) - BEATRISEUCTR2005-005399-34-PT.V. Roche S.A.800